NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NEI E-110-2005-2-CL-06 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE CL National Stage 2315-2006 Pending
NCI E-210-2006-0-US-01 Method of Detecting Hepatitis B Virus US 60/841,472 Abandoned
NIAID E-117-2006-0-US-01 Multiple BORIS Alternate Splice Forms As A Tool For Cancer Diagnostics And Treatment US 60/841,342 Abandoned
NEI E-110-2005-2-AU-03 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE AU National Stage 2006284841 Abandoned
NEI E-110-2005-2-ZA-16 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE ZA National Stage 2008/02379 Issued
NEI E-110-2005-2-CN-07 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE CN National Stage 200680040307.8 Issued
NEI E-110-2005-2-BA-18 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE BA EP 06813945.0 Issued
NEI E-110-2005-2-AL-17 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE AL EP 06813945.0 Expired
NEI E-110-2005-2-EP-08 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE EP National Stage 06813945.0 Issued
NEI E-110-2005-2-CY-19 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE CY National Stage 1933869 Issued
NINDS E-271-2005-0-PCT-02 Treatment and Prevention of Vascular Dementia PCT PCT PCT/US2006/034432 Expired
NEI E-110-2005-2-PCT-02 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE PCT PCT PCT/US2006/033840 Expired
NEI E-110-2005-2-US-01 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE US CIP 11/512,622 Abandoned
NEI E-110-2005-2-BR-04 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE BR National Stage PI0615297-0 Pending
NEI E-110-2005-2-MX-10 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE MX National Stage MX/a/2008/003100 Pending
NEI E-110-2005-2-EP-21 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE EP DIV 10180648.7 Pending
NEI E-110-2005-2-EP-20 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE EP DIV 09164605.9 Pending
NIEHS E-305-2005-0-PCT-02 DMT-DERIVATIVE COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE PCT PCT PCT/US2006/33560 Expired
NEI E-110-2005-2-TH-14 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE TH National Stage 601004157 Pending
NEI E-110-2005-2-JP-09 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE JP National Stage 2008-529228 Pending
NEI E-110-2005-2-PH-13 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE PH National Stage 1-2008-500508 Pending
NEI E-110-2005-2-NO-11 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE NO National Stage 20081574 Pending
NEI E-110-2005-2-CA-05 USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE CA National Stage 2621086 Abandoned
NCI E-274-2003-0-US-03 O4-Benzylpteridine Derivative As Inactivators Of The DNA Repair Protein, O6-Alkulguanine-DNA Alkyltransferase US National Stage 10/585,566 Abandoned
NCI E-253-1997-0-US-05 PB-39, A Gene Dysregulated in Prostate Cancer, and Uses Thereof US CON 11/511,259 Abandoned
NCI E-301-2006-0-US-01 Rapid Identification Of Genomic DNA Sequence Dimorphisms (indels) From Whole Genome Shotgun Sequencing Traces US 60/841,089 Abandoned
NCI E-103-2006-1-US-01 Methods And Compositions For Assessing Alterations In Gene Expression Patterns In Clinically Normal Tissues Obtained From Heterozygous Carriers Of Mutant Genes Associated With Cancer And Methods Of Use Thereof US 60/840,842 Abandoned
NIAID E-248-2006-1-US-01 A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs And A Mechanism For Enhanced Stability Of Foreign Gene Inserts By Codon Alteration And For Insertion Of Foreign Gene between Two Vaccinia Virus Essential Genes US 60/840,755 Abandoned
NIDDK E-056-2004-0-US-03 A NOVEL COFACTOR THAT MODULATES STEROID RECEPTOR ACTIVITIES. US National Stage 11/510,859 7867500 Abandoned PDF
NCI E-090-2009-0-US-01 Systems And Methods For High Throughput, Minimally-Invasive Radiation Biodosimetry US 60/840,245 Abandoned
NCI E-267-2006-0-US-01 COMBINATION THERAPY FOR THE TREATMENT OF CANCER US 60/840,216 Abandoned
NIAID E-302-2006-0-US-01 Epitope-Transplant Scaffolds and Their Use US 60/840,119 Abandoned
NIAID E-248-2006-0-US-01 A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs And A Mechanism For Enhanced Stability Of Foreign Gene Inserts By Codon Alteration And For Insertion Of Foreign Gene between Two Vaccinia Virus Essential Genes US 60/840,093 Abandoned
NCI E-094-2004-0-US-06 Pharmacodynamic Assays US National Stage 11/467,080 9389223 Abandoned PDF
NIDA E-234-2005-1-CA-02 BENZTROPINE COMPOUNDS AND USES THEREOF CA National Stage 2620418 Abandoned
NIDA E-234-2005-1-PCT-01 BENZTROPINE COMPOUNDS AND USES THEREOF PCT PCT COMB PCT/US2006/33103 Expired
NIDA E-234-2005-1-EP-03 BENZTROPINE COMPOUNDS AND USES THEREOF EP National Stage 06789971.6 Abandoned
NCI E-074-2004-0-US-03 Novel Design Of Pro-drugs Of The Antitumor Agent Zebularine Based On The Structures Of The Drug's Metabolites Isolated From Cell Cultures US National Stage 10/590,762 Abandoned
NIAID E-281-2006-0-US-01 Bacterial Peptides From Avian Leukocyte Ribonucleases US 60/840,268 Abandoned
NIDDK E-149-2006-0-US-01 Three Genes That Either Enhance Growth In HEK-293 Cells Or Modify Adhesion In HeLa Cells US 60/840,381 Abandoned
NCI E-169-1999-0-US-04 Peptides and Their Utility in Modulation of Behavior of Cells Expressing Alpha 3 Beta 1 Integrins US CON 11/466,718 7745144 Abandoned PDF
NIA E-059-2006-0-US-01 METHOD OF TREATING OR PREVENTING OXIDATIVE STRESS-RELATED DISEASE US 60/839,800 Abandoned
NCI E-110-2004-0-US-06 New Anti-tumor Phosphatase Inhibitors US National Stage 11/508,605 7504430 Abandoned PDF
NCI E-198-2006-0-US-01 Anti-HeN1 Influenza Activity Of The Antiviral Protein Cyanovirin-N (CV-N) US 60/838,712 Abandoned
NCI E-232-1998-0-US-05 Methods for Identifying Inhibitors of GADD45 Polypeptide Activity, and Inhibitors of Such Activity US DIV 11/506,947 7438892 Abandoned PDF
NCI E-217-2005-2-CA-03 Human Monoclonal Antibodies That Specifically Bind IGF-II CA National Stage 2618920 Abandoned
NCI E-217-2005-2-JP-05 Human Monoclonal Antibodies That Specifically Bind IGF-II JP National Stage 2008-527056 Abandoned
NCI E-217-2005-2-FR-09 Human Monoclonal Antibodies That Specifically Bind IGF-II
00371041
00371041
00371041
00371041 		FR EP 06789775.1 Abandoned
NCI E-217-2005-2-DE-08 Human Monoclonal Antibodies That Specifically Bind IGF-II
00371041
00371041
00371041
00371041 		DE EP 06789775.1 Abandoned
NCI E-217-2005-2-GB-10 Human Monoclonal Antibodies That Specifically Bind IGF-II
00371041
00371041
00371041
00371041 		GB EP 06789775.1 Abandoned